RE:RE:News Out The company has commenced a phase 2 NMIBC clinical study to enroll and treat patients who present with CIS and who are considered BCG unresponsive or are intolerant to BCG therapy. The company has three sites open for patient enrolment and treatment, specifically, University Health Network (UHN), McGill University Health Centre (MUHC) and London Health Sciences Centre (LHSC). All sites are actively recruiting and screening new patients for enrolment in study 2. In addition, the company has approximately six clinical study sites located in Canada and the United States that are at various stages of the on-boarding process. The company is specifically targeting strategic clinical sites throughout Canada and the United States (subject to Food and Drug Administration investigational new drug (IND) approval) that serve large populations or have the demographics to support patient enrolment and treatment. The company anticipates that patient enrolment and treatment will escalate rapidly as it launches additional clinical study sites.
in addition of the 3 sites in Canada there are 6 sites in Canada & US at various stages of on-boarding .... soon we will move up to 9 ..... slowly getting there.